Multiplex Assay Kit for Cathelicidin Antimicrobial Peptide (CAMP) ,etc. by FLIA (Flow Luminescence Immunoassay) 
CAP18; FALL39; HSD26; LL37; 18 kDa Cationic Antimicrobial Protein; Antibacterial protein FALL-39; FALL-39 peptide antibiotic
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 436.00 US$ 453.00 US$ 478.00 US$ 511.00 US$ 545.00 US$ 595.00 US$ 670.00 US$ 838.00
- Quantity
Overview
Properties
- Product No.LMC419Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Cathelicidin Antimicrobial Peptide (CAMP) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Cathelicidin Antimicrobial Peptide (CAMP) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 87-96 | 91 |
| EDTA plasma(n=5) | 93-101 | 97 |
| heparin plasma(n=5) | 78-101 | 92 |
| sodium citrate plasma(n=5) | 88-96 | 92 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cathelicidin Antimicrobial Peptide (CAMP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cathelicidin Antimicrobial Peptide (CAMP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cathelicidin Antimicrobial Peptide (CAMP) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 87-105% | 80-98% | 85-93% | 83-91% |
| EDTA plasma(n=5) | 95-103% | 98-105% | 92-101% | 84-98% |
| heparin plasma(n=5) | 95-102% | 90-98% | 85-99% | 80-101% |
| sodium citrate plasma(n=5) | 99-105% | 97-105% | 97-105% | 81-93% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:CAMP) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards,Labeled antigen and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest.A competitive inhibition reaction is launched between biotin labeled analytes of interest and unlabeled analytes of interest (Standards or samples) with the pre-coated antibody specific to analytes of interest. Following a wash to remove any unbound substances, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE) is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer. The MFI developed is reverse proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- The Assessment of Vitamin D, Antimicrobial Peptides and Procalcitonin in BronchiectasisWaikato:Source
- Host immune response to tuberculous meningitisPubmed:25301213
- On birth single dose live attenuated OPV and BCG vaccination induces gut cathelicidin LL37 responses at 6 week of age: A natural experimentPubmed:25444792
- Modulating the Internalization of Bacille Calmette-Guérin by Cathelicidin in Bladder Cancer Cells Pubmed:25681250
- Modulating the Internalization of Bacille Calmette-Guérin by Cathelicidin in Bladder Cancer CellsPubMed: 25681250
- Cathelicidin as a link between sarcoidosis and tuberculosisPubMed: 26422567
- The association of vitamin D, cathelicidin, and vitamin D binding protein with acute asthma attacks in childrenPubMed: 26108071
- Swiftly Decreasing Cerebrospinal Fluid Cathelicidin Concentration Predicts Improved Outcome in Childhood Bacterial Meningitis.Pubmed:27008883
- Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin.pubmed:27315464
- Reduced Expression of the Extracellular Calcium-Sensing Receptor (CaSR) Is Associated withActivation of the Renin-Angiotensin System (RAS) to Promote Vascular Remodeling in the Pathogenesis of Essential Hypertension.pubmed:27391973
- Ginsenoside Rg5 Inhibits Succinate-Associated Lipolysis in Adipose Tissue and Prevents Muscle Insulin Resistance.pubmed:28261091
- The relation of innate and adaptive immunity with viral-induced acute asthma attacks: Focusing on IP-10 and cathelicidinpubmed:27955890
- Effects of cold exposure on the bone marrow adipose tissueDOI: 10.3969/j.issn.1674-2591.2017.05.008
- Measurements of AMPs in stratum corneum of atopic dermatitis and healthy skin–tape stripping techniquePubmed:29374283
- Antimalarial activity of vitamin D3 (VD3) does not result from VD3-induced antimicrobial agents including nitric oxide or cathelicidinPubmed: 30904694
- Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signalingPubmed: 31149039
- Short-Term versus Long-Term Culture of A549 Cells for Evaluating the Effects of Lipopolysaccharide on Oxidative Stress, Surfactant Proteins and Cathelicidin LL-37Pubmed: 32050475
- Hypovitaminosis D and reduced cathelicidin are strongly correlated during the multidrug therapy against leprosyPubmed: 32645421
- Effect of Lonicerae japonicae Flos Carbonisata-Derived Carbon Dots on Rat Models of Fever and Hypothermia Induced by LipopolysaccharidePubmed: 32606669
- Relações causais entre a expressão dos genes do receptor de Vitamina D e do Peptídeo Antimicrobiano Catelicidina sobre marcadores sorológicos de pessoas com …
- Beneficial impact of cathelicidin on hypersensitivity pneumonitis treatment¡ªIn vivo studies33999928
- Analysis of the level of non-specific and specific immunity parameters in saliva of children with osteogenesis imperfecta and study of relationships between?¡
- Type I interferons link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea
- Compartmentalized Innate Immune Response of Human Fetal Membranes against Escherichia coli Choriodecidual InfectionPubmed:35328414
- LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunityPubmed:35649354